Shares of Synthetics Biologics, Inc. (NYSEMKT:SYN) added 3.59% by the end of trading session at $0.86. For the current quarter, the 5 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$0.08/share, which would compare with -$0.12 in the year-ago quarter. The net percentage change is -65.52% over the last 12 months. The trading range in the same period had a highest hit of $2.74 while lowest level was $0.73. At the moment the price is -28.43% below its 50-day moving average and -51.22% below its 200-day moving average.
Synthetics Biologics, Inc. (NYSEMKT:SYN) on December 13, 2016 announced that the United States Patent Office has granted U.S. Patent No. 9,512,204 which provides composition of matter coverage for SYN-005, the Company’s preclinical drug candidate designed to treat or prevent the development of Pertussis (whooping cough), especially in infants. This patent, which is co-owned with Synthetic Biologics’ Pertussis academic